Preterm Birth Patients Sought By US FDA As Meeting On Treatment Development Looms
With the only FDA-approved treatment off the market, the FDA is looking for ideas for development of new preterm birth treatments.
You may also be interested in...
Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be heading to make a dent in this multi-million-dollar market.
Organon has not strayed from its women’s health path, but is entering into earlier deals and considering technologies beyond therapeutics, while advocating increased investment in the field.
Approximately 41 months passed from the initial advisory committee meeting in October 2019 on Makena’s potential withdrawal to the 5 April 2023 final decision by FDA's commissioner and chief scientist - more than double the length of the same interval in the accelerated approval withdrawal proceeding involving the breast cancer claim for Genentech's Avastin.